Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

Archives of General Psychiatry
S KumraJ L Rapoport

Abstract

Childhood-onset schizophrenia is a rare but severe form of the disorder that is often treatment-refractory. In this study, the efficacy and adverse effects of clozapine and haloperidol were compared for children and adolescents with early-onset schizophrenia. Twenty-one patients (mean [+/-SD] age, 14.0 +/- 2.3 years) with onset of Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition-defined schizophrenia that began by age 12 years and who had been nonresponsive to typical neuroleptics participated in the study. Patients were randomized to a 6-week double-blind parallel comparison of clozapine (mean [+/-SD] final dose, 176 +/- 149 mg/d), or haloperidol, (16 +/- 8 mg/d). Clozapine was superior to haloperidol on all measures of psychosis (P = .04-.002). Positive and negative symptoms of schizophrenia improved. However, neutropenia and seizures were major concerns. To date, one third of the group has discontinued using clozapine. Clozapine has striking superiority for positive and negative symptoms in treatment-refractory childhood-onset schizophrenia. However, due to possibly increased toxic effects in this pediatric population, close monitoring for adverse events is essential.

Citations

Oct 15, 2013·European Psychiatry : the Journal of the Association of European Psychiatrists·C SchneiderS Frangou
Jul 4, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·UNKNOWN American Academy of Child and Adolescent Psychiatry
Aug 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Joanna Moncrieff
Sep 2, 2008·Journal of Child and Adolescent Psychopharmacology·Sanjiv KumraJohn M Kane
Oct 17, 2013·Indian Journal of Pharmacology·Siddharth Sarkar, Sandeep Grover
Jun 6, 2003·Psychological Bulletin·Kathryn E GrantJane A Halpert
Jan 25, 2003·Journal of Clinical Psychopharmacology·Jean A FrazierJudith L Rapoport
May 18, 2010·Journal of Clinical Psychopharmacology·Laure RagonnetSonia Dollfus
May 1, 2012·Journal of Clinical Psychopharmacology·David CohenClaudine Laurent
Feb 25, 1998·Journal of the American Academy of Child and Adolescent Psychiatry·S KumraJ L Rapoport
Apr 29, 1998·Journal of the American Academy of Child and Adolescent Psychiatry·S KumraJ L Rapoport
May 7, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·M CampbellG M Simpson
Oct 9, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·D CalderoniE Leibenluft
Jan 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Sarah B SchurPeter S Jensen
Jan 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Elizabeth PappadopulosPeter S Jensen
Jan 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Robert L FindlingS Charles Schulz
Apr 7, 2007·Journal of Psychiatric Practice·Humberto QuintanaDon Mercante
May 26, 2005·Schizophrenia Research·Peter A GochmanJudith L Rapoport
Aug 18, 2000·Paediatric Drugs·H RemschmidtE Schulz
Jan 5, 2002·Paediatric Drugs·K A StiglerC J McDougle
Jun 5, 1998·Journal of Child and Adolescent Psychiatric Nursing : Official Publication of the Association of Child and Adolescent Psychiatric Nurses, Inc·J K Warren
Oct 8, 2009·International Clinical Psychopharmacology·Harith S SwadiCandace M Bobier
Jan 13, 1999·Pediatric Clinics of North America·R L FindlingJ L Blumer
Dec 6, 2011·Journal of Child and Adolescent Psychopharmacology·Tamara PringsheimScott B Patten
Dec 15, 2011·Journal of Child and Adolescent Psychopharmacology·Lawrence Maayan, Christoph U Correll
Mar 21, 2013·Journal of Child and Adolescent Psychopharmacology·Kristin N MaherNitin Gogtay
Jan 1, 2007·International Journal of Psychiatry in Clinical Practice·Michal Hrdlicka, Iva Dudova
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·M V CheineM Rimón
Jul 19, 2012·Expert Opinion on Pharmacotherapy·Eric Fakra, Jean-Michel Azorin
Apr 3, 2013·Expert Review of Neurotherapeutics·Christopher N DavidNitin Gogtay
Apr 21, 2006·Expert Review of Neurotherapeutics·Claudio RuffmannEttore Beghi
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Suad Kapetanovic, George M Simpson
Aug 2, 2008·Expert Opinion on Pharmacotherapy·Vishal MadaanDaniel R Wilson
Mar 16, 2001·Expert Opinion on Pharmacotherapy·R L FindlingB L Gracious
Jan 22, 2010·Expert Opinion on Pharmacotherapy·Lisa Townsend, Robert L Findling
Mar 16, 2011·Expert Opinion on Drug Metabolism & Toxicology·Silvio CacciaMaurizio Bonati

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.